國家衛生研究院 NHRI:Item 3990099045/4903
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 854597      線上人數 : 729
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4903


    題名: Bacteremia due to extended-spectrum-beta-lactamase-producing enterobacter cloacae: Role of carbapenem therapy
    其他題名: Bacteremia due to extended-spectrum-β-lactamase-producing enterobacter cloacae: role of carbapenem therapy
    作者: Lee, CC;Lee, NY;Yan, JJ;Lee, HC;Chen, PL;Chang, CM;Wu, CJ;Ko, NY;Wang, LR;Chi, CH;Ko, WC
    貢獻者: Division of Infectious Diseases
    摘要: Enterobacter cloacae is one of important nosocomial pathogens. However, few studies specifically dealing with clinical characteristics and outcome of extended-spectrum beta-lactamase (ESBL)-producing E. cloacae infections have been published. During an eight-year period in a medical center, of 610 E. cloacae bacteremic isolates, 138 (22.6 %) with ESBL genes were designated as the ESBL group; and 120 (19.6 %) with cefotaxime-nonsusceptible without ESBL phenotype and genes as the control group. Of the former isolates, 133 (96.3%) had blaSHV-12, three (2.1%) blaCTX-M3, and two (1.4%) both blaSHV-12 and blaCTX-M3. After exclusion of age <18 year, there were 206 adults with E. cloacae bacteremia, 121 patients in the ESBL group and 85 in the control group. More episodes of hospital-onset and polymicrobial bacteremia, increased severity of illness, more bacteremic onset in intensive care units (ICUs), and longer stay in the hospital and ICU after bacteremic onset, were noted in the ESBL group. However, the crude and sepsis-related mortality rates in two groups were similar. Of the ESBL group, the in-hospital sepsis-related mortality rate of patients definitively treated by a carbapenem was lower than that of those by non-carbapenem ss-lactams (5/53, 9.4% vs. 13/44, 29.5%; P=0.01), though the difference was not significant in the hierarchical multivariate analysis (P=0.46). Among 62 patients with follow-up blood cultures within 14 days of bacteremic onset, breakthrough bacteremia was more common in those treated by a non-carbapenem beta-lactam agent than those treated by a carbapenem (18/31, 58.0% vs. 3/31, 9.6%; P<0.001). Thus, carbapenem therapy for ESBL-producing E. cloacae bacteremia may provide therapeutic benefits.
    日期: 2010-09
    關聯: Antimicrobial Agents and Chemotherapy. 2010 Sep;54(9):3551-3556.
    Link to: http://dx.doi.org/10.1128/aac.00055-10
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000281005900003
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77956129671
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB20547798.pdf314KbAdobe PDF844檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋